Holocene Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-3,270
Closed -$607K 734
2025
Q2
$607K Sell
3,270
-61,830
-95% -$11.5M ﹤0.01% 689
2025
Q1
$13.6M Sell
65,100
-1,042,042
-94% -$203M 0.04% 265
2024
Q4
$197M Buy
+1,107,142
New +$204M 0.63% 39
2024
Q3
Sell
-1,195,042
Closed -$205M 700
2024
Q2
$205M Sell
1,195,042
-47,967
-4% -$7.95M 0.86% 26
2024
Q1
$226M Sell
1,243,009
-417,484
-25% -$72M 0.83% 30
2023
Q4
$257M Buy
+1,660,493
New +$242M 1% 16
2022
Q1
Sell
-1,216,806
Closed -$165M 852
2021
Q4
$165M Sell
1,216,806
-596,047
-33% -$70.4M 0.86% 23
2021
Q3
$196M Buy
1,812,853
+729,682
+67% +$83.4M 1.06% 15
2021
Q2
$122M Buy
1,083,171
+195,231
+22% +$22M 0.69% 35
2021
Q1
$96.1M Sell
887,940
-354,514
-29% -$37.9M 0.6% 45
2020
Q4
$133M Buy
1,242,454
+158,628
+15% +$15.2M 0.84% 18
2020
Q3
$94.9M Buy
1,083,826
+466,355
+76% +$43.9M 0.72% 37
2020
Q2
$60.6M Buy
+617,471
New +$54.4M 0.53% 59

Other funds holding ABBV

Holocene Advisors's ABBV Position: Q3 2025 in Review

Holocene Advisors sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 3,270 shares — an estimated $607K sold.

Holocene Advisors first reported a position in ABBV in Q2 2020 and held it in 13 quarters. The position peaked at $257M in Q4 2023. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Holocene Advisors reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
  • Holocene Advisors sold 3,270 AbbVie shares in Q3 2025, an estimated $607K.
  • Holocene Advisors first reported a position in AbbVie in Q2 2020 and held it in 13 quarters.
  • Holocene Advisors's AbbVie position peaked at $257M in Q4 2023.
  • 3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Holocene Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.